CSX (NASDAQ:CSX – Free Report) had its price objective trimmed by Barclays from $41.00 to $40.00 in a research note issued to investors on Friday,Benzinga reports. The firm currently has an overweight rating on the transportation company’s stock.

Saia (NASDAQ:SAIA – Free Report) had its price target trimmed by Barclays from $620.00 to $600.00 in a report published on Friday,Benzinga reports. The brokerage currently has an overweight rating on the transportation company’s stock.

In a report released today, Richard Taylor from Barclays maintained a Buy rating on IG Group Holdings (IGG – Research Report), with a price

In a report released today, Benjamin Budish from Barclays maintained a Buy rating on Carlyle Group (CG – Research Report), with a price target

Public Service Enterprise Group Inc (PEG) stock saw a decline, ending the day at $88.14 which represents a decrease of $-0.34 or -0.38% from the prior close of $88.48. The stock opened at $88.3 and touched a low of $87.

Jefferies has upgraded Safran Groups stock rating to buy from hold, citing robust growth prospects and appealing opportunities for long-term investors. The decision follows Safrans Capital Markets Day,

Public Service Enterprise Group Inc (PEG) stock saw a modest uptick, ending the day at $86.27 which represents a slight increase of $1.21 or 1.42% from the prior close of $85.06. The stock opened at $86.

While London South East do their best to maintain the high quality of the information displayed on this site, we cannot

We recently compiled a list of the Top 10 AI Stocks on Latest Analyst Ratings and News. In this article, we are going to take a look at where Broadcom Inc. (NASDAQ:AVGO) stands against the other AI stocks.

Clorox (NYSE:CLX – Free Report) had its target price cut by Barclays from $139.00 to $130.00 in a research report report published on Friday morning,Benzinga reports. They currently have an underweight rating on the stock.

European markets start the new trading week flat, with market attention on the inauguration of U.S. President-elect Donald Trump.

According to Evaluate Pharma, China's growing influence in pharmaceutical R&D is a key theme to watch in 2025. The pharma research group said that a Chinese company represents at least a fifth of R&D programs in the industry's total clinical pipeline.